Bio-Techne Corporation TECH
Super Investor & Insider
4
Fondi che lo detengono
#200
Rank consenso
5.7%
% dei portafogli
$658.4M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Lee Ainslie · Maverick Capital | 2.88% | Add 23.08% | 4,739,721 | $247.7M |
| Henry Ellenbogen · Durable Capital Partners | 2.4% | Add 113.32% | 4,456,017 | $232.9M |
| Mairs & Power · Mairs & Power | 1.47% | Reduce 0.62% | 2,750,282 | $143.7M |
| Wallace Weitz · Weitz Investment Management | 2.38% | Reduce 18.65% | 653,200 | $34.1M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Bio-Techne Corporation is a global life sciences company that develops, manufactures, and supplies specialized tools for research and clinical diagnostics. The company focuses on high-quality reagents, analytical instruments, and precision diagnostic products used across pharmaceutical, biotechnology, academic, and cli…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees3,100
TickerTECH
Statistics
Market Cap$8.57B
Revenue (TTM)$1.22B
Net Income$73.4M
Net Margin6.0%
EPS$0.46
P/E77.17
P/S6.99
P/B4.19
EV/EBITDA22.66
ROE5.3%
Dividend Yield0.59%
Price$54.77
Data: Twelve Data · Revenue = mcap / P/S